Todas las investigaciones
Activo, no reclutandoFASE1, FASE2INTERVENCIONISTA

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

This research study is investigating a new medication, DYNE-101, for individuals living with Myotonic Dystrophy Type 1 (DM1). The main goals are to find out if DYNE-101 is safe, how well people tolerate ongoing treatment, and if it has any positive effects on their condition. Participants will receive either DYNE-101 or a placebo (a dummy medicine) through an intravenous (IV) drip, meaning it goes directly into a vein. The study is divided into several stages, including an initial screening, a period where some receive placebo, followed by a treatment period, and a long-term follow-up. We'll be carefully monitoring participants' health and DM1 symptoms throughout to understand the medicine's potential.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE1, FASE2
Patrocinador
Dyne Terapéutica
Objetivo de inscripción
127
Inicio
05 Sep 2022
Estimación de finalización
01 Jul 2029

¿De qué trata este estudio?

This study focuses on Myotonic Dystrophy Type 1, often shortened to DM1, which is a genetic condition that causes muscles to weaken and waste over time. It can affect many parts of the body, including the heart and brain, but muscle problems are usually the most noticeable. Researchers are always looking for new ways to help manage DM1 and improve the lives of people living with it.

This particular study is testing a new medicine called DYNE-101. It's designed to see if it can help with the symptoms of DM1. They want to check a few things: first, if the medicine is safe and if people can handle taking it over time without too many side effects (this is called 'safety and tolerability'). Second, they want to see if it changes certain things in your body related to DM1 (this is called 'pharmacodynamics') and how your body processes the medicine ('pharmacokinetics'). Finally, they're looking to see if it actually helps improve symptoms or slows down the condition ('efficacy').

Because this is a new medicine, the study is split into different stages – Phase 1 and Phase 2. This means they are carefully increasing the number of people involved and the amount of information they gather about the medicine. Some participants will receive the actual medicine, while others will get a placebo, which looks like the medicine but has no active ingredients. This helps researchers understand whether any changes they see are truly due to the new medicine or not. This is a common and important way to test new treatments.

Puntos clave

  • This study is for people with Myotonic Dystrophy Type 1 (DM1).
  • It tests a new medicine called DYNE-101.
  • The main goals are to check safety, tolerability, and potential benefits.
  • Participation involves IV infusions and regular clinic visits.
  • Some participants will receive a placebo, not the active medicine.
  • The study has a long-term follow-up period.

¿Quién puede ser elegible?

To join this study, you must have a confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1) with a specific genetic marker. Your DM1 muscle symptoms must have started when you were 12 years old or older. You also need to be between 18 and 65 years old. The doctors will check your muscle strength, especially in your hands and ankles, and make sure you have noticeable myotonia (muscles finding it hard to relax).

There are also some requirements about your physical abilities. For example, you should be able to walk a certain distance in 10 minutes, climb stairs, and stand up from a chair five times in a row without needing walking aids like canes or walkers. This helps ensure you can safely complete the study assessments.

However, you won't be able to join if you've had major surgery recently or expect to have one during the study, or if you've had a severe allergic reaction in the past. Other reasons you might not be eligible include certain heart conditions, breathing problems, recent history of suicidal thoughts, or if you're taking certain medications that could interfere with the study. The study team will review all your health information carefully to determine if this study is suitable and safe for you.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. Do I have a confirmed diagnosis of Myotonic Dystrophy Type 1?
  2. Are my DM1 muscle symptoms confirmed to have started when I was 12 years old or older?
  3. Am I between 18 and 65 years old?
  4. Can I walk a short distance, climb stairs, and stand up from a chair several times without help?
  5. Do I have fairly noticeable muscle stiffness (myotonia)?
  6. Have I avoided major surgery recently and don't expect one during the study?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you join this study, it will involve several stages over a long period. First, there's a screening period stretching up to 8 weeks to check if you're suitable. After that, some participants will receive a placebo (dummy medicine) for 24 weeks, while others will eventually receive DYNE-101. This is followed by a main treatment period of 24 weeks where you'll receive the study medicine, and then a long-term follow-up that could last up to 168 weeks (about 3 years and 3 months).

The study medicine, DYNE-101, will be given through an intravenous (IV) drip, meaning it's put directly into a vein. You'll have regular visits to the clinic for these infusions, as well as for various assessments. These assessments will include physical exams, checking your muscle strength and movement, possibly blood tests, heart checks like ECGs, and answering questions about your symptoms and how you're feeling. The exact number of visits will depend on which stage of the study you are in, but generally, expect frequent visits, especially at the beginning.

Riesgos y beneficios potenciales

Like all clinical studies, participating in this research has potential benefits and risks. You might benefit from receiving a new medicine for your DM1 that isn't yet widely available, and your health will be closely monitored by a specialist medical team. However, there's no guarantee that DYNE-101 will improve your condition, or that you won't receive the placebo. Potential risks could include side effects from the study medicine, discomfort from blood tests or IV infusions, and the time commitment involved in clinic visits. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (20)

  • Stanford University
    Código postal verificado
    Stanford, United States
  • University of Florida College of Medicine
    Código postal verificado
    Gainesville, Estados Unidos
  • Indiana University School of Medicine
    Código postal verificado
    Indianápolis, Estados Unidos
  • University of Iowa
    Código postal verificado
    Iowa City, Estados Unidos
  • Universidad de Washington en San Luis
    Código postal verificado
    San Luis, Estados Unidos
  • University of Rochester Medical Center
    Código postal verificado
    Rochester, United States
  • Neurology Rare Disease Center
    Código postal verificado
    Denton, United States
  • Virginia Commonwealth University (VCU)
    Código postal verificado
    Richmond, Estados Unidos
  • St. Vincent's Hospital
    Código postal verificado
    Fitzroy, Australia
  • CHU de Nantes
    Código postal verificado
    Nantes, France
  • Institut de Myologie
    Código postal verificado
    París, Francia
  • Charité - Universitätsmedizin Berlin
    Código postal verificado
    Berlín, Alemania

Preguntas comunes

What is Myotonic Dystrophy Type 1 (DM1)?

DM1 is a genetic condition that causes muscles to weaken, can affect the heart, and might lead to other health issues.

What is DYNE-101?

DYNE-101 is a new investigational medicine being tested to see if it can help people with DM1.

¿Definitivamente recibiré el nuevo medicamento?

Not necessarily. In some parts of the study, participants might receive a placebo (a dummy medicine with no active ingredients).

How is the medicine given?

The medicine is given through an intravenous (IV) drip, which means it goes directly into a vein.

¿Cuánto tiempo durará el estudio?

The study involves different periods, including screening, a placebo period, a treatment period, and a long-term follow-up that could last over three years total.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.